Inflammatory and redox reactions in colorectal carcinogenesis

Annals of the New York Academy of Sciences

Volumn 1340, Issue 1, 2015, Pages 95-103

  Guina, Tina ^a   Biasi, Fiorella ^a   Calfapietra, Simone ^a   Nano, Mario ^b   Poli, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Antioxidant response; Colorectal cancer; Inflammatory bowel disease; Reactive oxygen species

Indexed keywords

AUTACOID; REACTIVE OXYGEN METABOLITE;

ANIMAL; ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL NEOPLASMS; DIAGNOSIS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; COLORECTAL NEOPLASMS; DIAGNOSIS; HUMANS; INFLAMMATION MEDIATORS; METABOLISM; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHYSIOLOGY; RISK FACTORS;

EID: 84963955533     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12734     Document Type: Article

References (50)

1. Ferlay, J., I. Soerjomataram, R. Dikshit, et al. 2014. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136: E359-E386.
2. Lovasz, B.D., L. Lakatos, A. Horvath, et al. 2013. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort. World J. Gastroenterol. 19: 2217-2226.
3. Kim, E.R. & D.K. Chang. 2014. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol. 20: 9872-9881.
4. Biasi, F., G. Leonarduzzi, P.I. Oteiza & G. Poli. 2013. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid. Redox Signal. 19: 1711-1747.
5. Perše, M. 2013. Oxidative stress in the pathogenesis of colorectal cancer: cause or consequence? Biomed. Res. Int. 2013: Article ID: 725710, Open access article, doi: 10.1155/2013/725710.
6. Mangerich, A., P.C. Dedon, J.G. Fox, et al. Chemistry meets biology in colitis-associated carcinogenesis. Free Radic. Res. 47: 958-986.
7. Galon, J., A. Costes, F. Sanchez-Cabo, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
8. Götlind, Y.Y., M. Fritsch Fredin, A.K. Kumawat, et al. 2013. Interplay between T(h)1 and T(h)17 effector T-cell pathways in the pathogenesis of spontaneous colitis and colon cancer in the Gαi2-deficient mouse. Int. Immunol. 25: 35-44.
9. Edin, S., M.L. Wikberg, A.M. Dahlin, et al. 2012. The distribution of macrophages with a m1 or m2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7: e47045.
10. Galdiero, M.R., C. Garlanda, S. Jaillon, et al. 2013. Tumor associated macrophages and neutrophils in tumor progression. J. Cell Physiol. 228: 1404-1412.
11. Shang, K., Y.P. Bai, C. Wang, et al. 2012. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One 7: e51848.
12. Absenger, G., J. Szkandera, M. Pichler, et al. 2013. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br. J. Cancer 109: 395-400.
13. Grivennikov, S.I. 2013. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin. Immunopathol. 35: 229-244.
14. Wang, D. & R.N. Dubois. 2010. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788.
15. Bellamkonda, K., W. Sime & A. Sjölander. 2014. The impact of inflammatory lipid mediators on colon cancer-initiating cells. Mol. Carcinog. doi: 10.1002/mc.22207. [Epub ahead of print].
16. DeSimone, V., E. Franzè, G. Ronchetti, et al. 2014. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene doi: 10.1038/onc.2014.286. [Epub ahead of print].
17. Klapproth, J.M. & M. Sasaki. 2010. Bacterial induction of proinflammatory cytokines in inflammatory bowel disease. Inflamm. Bowel Dis. 16: 2173-2179.
18. Lee, Y.S., I. Choi, Y. Ning, et al. 2012. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br. J. Cancer 106: 1833-1841.
19. Biasi, F., T. Guina, M. Maina, et al. 2012. Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract. PLoS One 7: e41839.
20. Waldner, M.J., S. Foersch & M.F. Neurath. 2012. Interleukin-6-a key regulator of colorectal cancer development. Int. J. Biol. Sci. 8: 1248-1253.
21. Yu, L.Z., H.Y. Wang, S.P. Yang, et al. 2013. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J. Gastroenterol. 19: 2638-2649.
22. Omrane, I., O. Baroudi, K. Bougatef, et al. 2014. Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer. Immunol. Lett. 158: 189-194.
23. Fleming, N.I., R.N. Jorissen, D. Mouradov, et al. 2013. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 73: 725-735.
24. Sipos, F. & O. Galamb. 2012. Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon. World J. Gastroenterol. 18: 601-608.
25. Juhasz, A., Y. Ge, S. Markel, et al. 2009. Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Rad. Res. 43: 523-532.
26. Kuwano, Y., K. Tominaga, T. Kawahara, et al. 2008. Tumor necrosis factor alpha activates transcription of the NADPH oxidase organizer 1 (NOXO1) gene and upregulates superoxide production in colon epithelial cells. Free Radic. Biol. Med. 45: 1642-1652.
27. Tardieu, D., J.P. Jaeg, A. Deloly, et al. 2000. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973-976.
28. Dincer, Y., Y. Erzin, S. Himmetoglu, et al. 2007. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig. Dis. Sci. 52: 1636-1641.
29. Hussain, S.P., P. Amstad, K. Raja, et al. 2000. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60: 3333-3337.
30. Nishikawa, M., N. Oshitani, T. Matsumoto, et al. 2005. Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br. J. Cancer 93: 331-337.
31. Poli, G., R.J. Schaur, W.G. Siems & G. Leonarduzzi. 2008. 4-hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med. Res. Rev. 28: 569-631.
32. Rokutan, K., T. Kawahara, Y. Kuwano, et al. 2006. NADPH oxidases in the gastrointestinal tract: a potential role of Nox1 in innate immune response and carcinogenesis. Antioxid. Redox Signal. 8: 1573-1582.
33. Arbiser, J.L., J. Petros, R. Klafter, et al. 2002. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. U.S.A. 99: 715-720.
34. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
35. Vogler, M. 2012. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 19: 67-74.
36. Berardi, R., E. Maccaroni, A. Mandolesi, et al. 2012. Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. Dig. Liver Dis. 44: 617-622.
37. Neish, A.S. 2013. Redox signaling mediated by the gut microbiota. Free Radic. Res. 47: 950-957.
38. Slattery, M.L., A. Lundgreen, S.A. Kadlubar, et al. 2013. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol. Carcinog. 52: 155-166.
39. He, Z., X. He, Z. Chen, et al. 2014. Activation of the mTORC1 and STAT3 pathways promotes the malignant transformation of colitis in mice. Oncol. Rep. 32: 1873-1880.
40. Wu, S., K.J. Rhee, E. Albesiano, et al. 2009. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15: 1016-1022.
41. Geismann, C., A. Arlt, S. Sebens & H. Schäfer. 2014. Cytoprotection "gone astray": Nrf2 and its role in cancer. Onco. Targets Ther. 7: 1497-1518.
42. Gañán-Gómez, I., Y. Wei, H. Yang, et al. 2013. Oncogenic functions of the transcription factor Nrf2. Free Radic. Biol. Med. 65: 750-764.
43. Gorrini, C., I.S. Harris & T.W. Mak. 2013. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12: 931-947.
44. Kim, J., Y.N. Cha & Y.J. Surh. 2010. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat. Res. 690: 12-23.
45. Rushworth, S.A., L. Zaitseva, M.Y. Murray, et al. 2012. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance. Blood 120: 5188-5198.
46. Yin, H., J. Fang, L. Liao, et al. 2014. Upregulation of heme oxygenase-1 in colorectal cancer patients with increased circulation carbon monoxide levels, potentially affects chemotherapeutic sensitivity. BMC Cancer 14: 436.
47. Was, H., J. Dulak & A. Jozkowicz. 2010. Heme oxygenase-1 in tumor biology and therapy. Curr. Drug Targets 11: 1551-1570.
48. Andrés, N.C., M.E. Fermento, N.A. Gandini, et al. 2014. Heme oxygenase-1 has antitumoral effects in colorectal cancer: Involvement of p53. Exp. Mol. Pathol. 97: 321-331.
49. Becker, J.C., H. Fukui, Y. Imai, et al. 2007. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand. J. Gastroenterol. 42: 852-858.
50. Ribeiro, M.L., D.G. Priolli, D.D. Miranda, et al. 2008. Analysis of oxidative DNA damage in patients with colorectal cancer. Clin. Colorectal Cancer 7: 267-272.